Neil N Senzer
Overview
Explore the profile of Neil N Senzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jamieson S, Tsai P, Kondratyev M, Budhani P, Liu A, Senzer N, et al.
JCI Insight
. 2023 Feb;
8(4).
PMID: 36810255
No abstract available.
2.
Jamieson S, Tsai P, Kondratyev M, Budhani P, Liu A, Senzer N, et al.
JCI Insight
. 2018 Aug;
3(16).
PMID: 30135316
Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which...
3.
Kaufman H, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, et al.
J Immunother Cancer
. 2016 Mar;
4:12.
PMID: 26981242
Background: We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma...
4.
Mahalingam D, Nemunaitis J, Malik L, Sarantopoulos J, Weitman S, Sankhala K, et al.
Cancer Chemother Pharmacol
. 2014 Oct;
74(6):1241-50.
PMID: 25304209
Purpose: ATI-1123 is a liposomal formulation of docetaxel and may be administered without the premedications and hypersensitivity reactions. This Phase I study examines the safety, tolerability, pharmacokinetics (PKs), and antitumor...
5.
Goyal L, Supko J, Berlin J, Blaszkowsky L, Carpenter A, Heuman D, et al.
Cancer Chemother Pharmacol
. 2013 Oct;
72(6):1305-14.
PMID: 24121453
Purpose: N(1),N(11)-diethylnorspermine (DENSPM), a synthetic analog of the naturally occurring polyamine spermine, can induce polyamine depletion and inhibit tumor cell growth. The objectives of this phase I study were to...
6.
Rudin C, Poirier J, Senzer N, Stephenson Jr J, Loesch D, Burroughs K, et al.
Clin Cancer Res
. 2011 Feb;
17(4):888-95.
PMID: 21304001
Purpose: Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a...
7.
Nemunaitis J, Senzer N
F1000 Biol Rep
. 2010 Oct;
1:35.
PMID: 20948650
Cancer-cell survival, growth and metastatic potential are directed by dominant molecular signalling patterns, the components of which have been shown to be qualitatively different from their normal tissue counterparts. These...
8.
Sequist L, Gettinger S, Senzer N, Martins R, Janne P, Lilenbaum R, et al.
J Clin Oncol
. 2010 Oct;
28(33):4953-60.
PMID: 20940188
Purpose: IPI-504 is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90). Its potential anticancer activity has been validated in preclinical in vitro and in vivo models. We studied...
9.
Loesch D, Greco F, Senzer N, Burris H, Hainsworth J, Jones S, et al.
J Clin Oncol
. 2010 May;
28(18):2958-65.
PMID: 20479419
Purpose: This study compared disease-free survival (DFS) obtained with two different regimens of adjuvant therapy in high-risk breast cancer. Methods: Women (who had performance status [PS] of 0 to 1)...
10.
Senzer N, Kaufman H, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al.
J Clin Oncol
. 2009 Nov;
27(34):5763-71.
PMID: 19884534
Purpose: Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF) in stages IIIc and IV disease. Patients...